In addition, suppression of tumor cell viability by the co-inhibition of FAK and BRD4 is nearly equivalent to the targeted or chemo- therapeutic agents being employed for treatment of NSCLC. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.